Sun Pharmaceutical Industries Limited appears to be a financially stable company with a strong gross margin of 79.56% and EBITDA margin of 28.69%, indicating efficient operations. The company's high trailing P/E ratio of 36.48 and forward P/E ratio of 50.85 suggest that it may be overvalued. A weakness is the decline in earnings growth (-18.8%) and moderate revenue growth (8.1%). The company's debt-to-equity ratio of 3.26 is a concern, but its dividend yield of 0.66% and book value of 302.33 suggest a relatively stable financial position. Overall, the company's financial health is decent, but investors should be cautious of the high valuation and debt levels.